Looks like AMBS followed through on a LOI. This su
Post# of 30028
OCTOBER 03, 2013 - Amarantus Enters Into Letter of Intent With Renishaw for Convection-Enhanced Delivery of MANF in Parkinson's Disease
Quote:
Over the course of the next 12 months, the companies will collaborate to conduct certain feasibility studies to ensure the long-term viability of delivering MANF using Renishaw's product line to key brain structures. If successful, the companies expect to enter into a definitive agreement to support human clinical studies and commercial use.
http://www.amarantus.com/news/press-releases/...nishaw-for
MAY 15, 2015 - Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
Quote:
The Company expects to publish further data from this study in peer-reviewed journals and at scientific congresses over the course of 2015.
http://www.amarantus.com/news/press-releases/...ibution-of
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
http://www.amarantus.com/news/press-releases/...n-targeted